1. The role of exercise-induced myokines in regulating metabolism
   Joo Young Huh, 2018, Arch. Pharm. Res. CrossRef
2. EFFECTS OF THE BETA 2 AGONIST FORMOTEROL ON ATROPHY SIGNALING, AUTOPHAGY, AND MUSCLE PHENOTYPE IN RESPIRATORY AND LIMB MUSCLES OF RATS WITH CANCER-INDUCED CACHEXIA
   Anna Salazar-Degracia et al, 2018, Biochimie CrossRef
3. Mitochondrial dynamics in cancer-induced cachexia
   Miranda van der Ende et al, 2018, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer CrossRef
4. NEW INSIGHTS ON THE REGULATION OF CANCER CACHEXIA BY N-3 POLYUNSATURATED FATTY ACIDS
   Renata Gorjao et al, 2018, Pharmacology & Therapeutics CrossRef
5. Muscle Wasting Diseases: Novel Targets and Treatments
   Regula Furrer et al, 2019, Annu. Rev. Pharmacol. Toxicol. CrossRef
6. Differential structural features in soleus and gastrocnemius of carnitine-treated cancer cachectic rats.
   Sílvia Busquets et al, 2020, J Cell Physiol CrossRef
7. A differential pattern of gene expression in skeletal muscle of tumor-bearing rats reveals dysregulation of excitation-contraction coupling together with additional muscle alterations
   Cibely Cristine Fontes-Oliveira et al, 2014, Muscle Nerve CrossRef
8. β2-Adrenergic agonists and the treatment of skeletal muscle wasting disorders
   Olivier R. Joassard et al, 2013, The International Journal of Biochemistry & Cell Biology CrossRef
9. The anabolic catabolic transforming agent (ACTA) espindolol increases muscle mass and decreases fat mass in old rats
   Mareike S. Pötsch et al, 2014, J Cachexia Sarcopenia Muscle CrossRef
10. Myostatin — From the Mighty Mouse to cardiovascular disease and cachexia
    Thomas Bernd Dschietzig, 2014, Clinica Chimica Acta CrossRef
11. Muscle wasting: An overview of recent developments in basic research
    Sandra Palus et al, 2014, International Journal of Cardiology CrossRef
12. Muscle wasting: an overview of recent developments in basic research
    Sandra Palus et al, 2014, J Cachexia Sarcopenia Muscle CrossRef
13. Skeletal muscle atrophy: Potential therapeutic agents and their mechanisms of action
    Vikas Dutt et al, 2015, Pharmacological Research CrossRef
14. Mechanisms underlying enhancements in muscle force and power output during maximal cycle ergometer exercise induced by chronic β2-adrenergic stimulation in men
    Morten Hostrup et al, 2015, Journal of Applied Physiology CrossRef
15. Cardiac cachexia: hic et nunc
    Goran Loncar et al, 2015, International Journal of Cardiology CrossRef
16. Beta2-Agonist Doping Control and Optical Isomer Challenges
    Glenn A. Jacobson et al, 2016, Sports Med CrossRef
17. Formoterol decreases muscle wasting as well as inflammation in the rat model of rheumatoid arthritis
    Ana Belén Gómez-SanMiguel et al, 2016, American Journal of Physiology-Endocrinology and Metabolism CrossRef
18. Formoterol attenuates increased oxidative stress and myosin protein loss in respiratory and limb muscles of cancer cachectic rats
    Anna Salazar-Degracia et al, 2017 CrossRef
19. Cancer-Associated Cachexia: A Systemic Consequence of Cancer Progression
    Anup K. Biswas et al, 2020, Annu. Rev. Cancer Biol. CrossRef
20. Counteracting Muscle Atrophy on Earth and in Space via Nanofluidics Delivery of Formoterol
    Andrea Ballerini et al, 2020, Adv. Therap. CrossRef
21. null
    Linlin Chen et al, 2021 CrossRef
22. β2-Adrenergic agonist salbutamol augments hypertrophy in MHCIIa fibers and sprint mean power output but not muscle force during 11 weeks of resistance training in young men
    Søren Jessen et al, 2021, Journal of Applied Physiology CrossRef
23. Polyphenols and Their Effects on Muscle Atrophy and Muscle Health
    Takeshi Nikawa et al, 2021, Molecules CrossRef
24. Skeletal Muscle Deconditioning in Breast Cancer Patients Undergoing Chemotherapy: Current Knowledge and Insights From Other Cancers
    Joris Mallard et al, 2021, Front. Cell Dev. Biol. CrossRef
25. Cancer cachexia: molecular mechanisms and treatment strategies
    Tania Setiawan et al, 2023, J Hematol Oncol CrossRef